BREAST CANCER BASE

The study found increases in breast cancer-related gene Canada's McGill University researchers recently discovered a can promote breast cancer tumor cell growth gene. This discovery will crea...

Bra overextended easy carcinogenic Cardiff, Wales, UK The doctor did a study showed that women will Dairuzhao breast pain and the risk there cyst increased significantly, it ...

American Society of Clinical Oncology annual meeting of a recently released study shows that cholesterol-lowering drugs, "Johns Hopkins University," at least 50% lower risk of developing breast cancer, but its safety and effectiveness is yet to be verified.

Louisiana State University Health Science Center researchers access to the 1998-2004 United States Department of Veterans Affairs responsible for the care of the retired female soldier recorded and compared 556 women with breast cancer and 39,865 healthy women taking "Johns Hopkins University." The results found that in six years of the course of the study, those who use, "Johns Hopkins University," women's risk of developing breast cancer than those who do not use "to analyze" the lower 51% of women.

Researchers also discovered through laboratory research, known as HMG-CoA enzyme in the cancer cell proliferation will play a role, "Johns Hopkins University," can inhibit this enzyme activity, thus impeding the process of carcinogenesis and prevent tumor formation. Researchers said this is only the "Johns Hopkins University," a role, it may also help to use "Johns Hopkins University," women reduce cancer risk.

Researchers also pointed out that "to analyze" reduce cancer risk mechanism of action has not yet fully understand, and now recommend that people use "widely used" to reduce the risk of cancer too early. The medical community needs further study to prove "to analyze" the anti-cancer effects and safety. But for excessive levels of cholesterol in patients, "Johns Hopkins University," will undoubtedly be a better choice.

Cholesterol-lowering drugs are often used to combat cardiovascular diseases, "Johns Hopkins University," is the cholesterol-lowering drugs, the most important one category, it works by blocking the body's synthesis of cholesterol lowering cholesterol to achieve the purpose.

According to Agence France-Presse reported on the 15th, the American Society of Clinical Oncology annual meeting released a research report said that the history of statins (Statins) for the cholesterol-lowering drugs known breast cancer risk reduction of 50% or more.

According to several recent independent study shows that the history of statins can also lower the risk of lung cancer and prostate cancer risk reduction were 48% and 54%. Lipitor simvastatin and other common cholesterol-lowering drug containing the history of statins.

Louisiana University Health Science Center, Center for Khurana, an assistant professor of medicine is the study's authors. His May 14 in the American Society of Clinical Oncology annual meeting, said : "I think that for those women at high risk of breast cancer, history of statins is a very important preventive role." However, Khurana, to tell people they should take the drugs to reduce the risk of cancer too early.

The researchers compared the 556 patients with breast cancer and 39,865 women have never won a disease of women using statins history of the results.

Britain's "The Times" on May 14 reported that the tests showed that those with early stage HER-2 breast cancer in women after surgery, in addition to taking the standard drugs plus drug Herceptin (Herceptin), the disease would reduce the recurrence rate of 46%. About 20% to 30% of women can benefit from this therapy, because their tumors on the HER-2 protein sensitive. Experts believe that the discovery may be the treatment of breast cancer over the years of a big leap. Initial findings suggest that the early use of Herceptin, in the United Kingdom each year could save more than 2,800 HER-2 breast cancer patients their lives.

Test results are American Society of Clinical Oncology in Orlando, Florida, at the meeting announced. Total 5
000 patients of whom 500 received from the United Kingdom-a clinical trial.

London's Royal Marsden Hospital, director of breast Professor Smith said : "This exciting test results, the treatment of breast cancer has become a landmark. For those with HER-2 breast cancer patients, it is very important progress. Now we need to rapidly develop plans to measure most of the all breast cancer patients HER-2, in order to determine which patients can benefit from this therapy. "At present, only 35% of Britain's Cancer Center in the diagnosis of breast cancer testing HER-2 status.

Exercise can reduce breast cancer treatment side effects Many of the patients with early breast cancer after receiving treatment there will be fatigue, nausea, anxiety and other debilitating sympt...

Female obesity may indicate breast cancer The American Cancer Society in a recent research report pointed out that female weight gain is likely to be the future risk of breast cance...

Study says eating cabbage, sprouts and chemotherapy for breast cancer results According to the "Daily Mail" reported on the 11th, the University of Leicester, United Kingdom researchers recently discovered t...

Women should do regular breast examination A study shows that women should do regular breast screening to prevent the development of advanced breast cancer, delay in treatment time. ...

Breast cancer diagnosis: MRI substitute for biopsy Breast magnetic resonance imaging (MRI) in the clinical application of increasingly widespread, but at the Johns Hopkins University Bluemke...

Restaurants and sunlight exposure and the incidence of breast cancer One pair of different national diet studies have confirmed that eating too much animal fat and the incidence of breast cancer among relevan...

Acceleration of breast irradiation

Cadmium exposure may result in breast cancer